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Abstract Carbohydrate-deficient glycoprotein syndrome type I
(CDGI) is most often due to phosphomannomutase deficiency;
paradoxically, the human phosphomannomutase gene PMM1 is
located on chromosome 22, whereas the CDGI locus is on
chromosome 16. We show that phosphomannomutases present in
rat or human liver share with homogeneous recombinant PMM1
several kinetic properties and the ability to form an alkali- and
NH
2
OH-sensitive phosphoenzyme with a subunit mass of
W30 000 M
r
. However, they have a higher affinity for the
activator mannose-1,6-bisphosphate than PMM1 and are not
recognized by anti-PMM1 antibodies, indicating that they
represent a related but different isozyme. Phosphomannomutases
belong to a novel mutase family in which the active residue is a
phosphoaspartyl or a phosphoglutamyl.
z 1997 Federation of European Biochemical Societies.
1. Introduction
Carbohydrate-de¢cient glycoprotein syndromes (CDG) are
multisystemic disorders characterized by a de¢ciency in the N-
glycosylation of serum and cellular proteins [1,2]. The type I
syndrome, by far the most frequent type, is an autosomal
recessive disorder. Linkage studies have assigned the corre-
sponding locus to the short arm of chromosome 16 [3^5].
Van Schaftingen and Jaeken reported in 1995 that phospho-
mannomutase activity was de¢cient in liver, leucocytes and/or
¢broblasts of six patients with CDG type I [6]. This de¢ciency
has now been con¢rmed in cells from 45 out of 52 patients [7].
The seven other cases are presumably due to a di¡erent en-
zyme de¢ciency.
Two di¡erent types of phosphomannomutases have been
described. In prokaryotes, the enzyme is a W50 000 M
r
poly-
peptide that has the consensus phosphorylation site
(TASHNP) of phosphoglucomutases from prokaryotes and
eukaryotes [8^11]. In contrast, phosphomannomutases of Sac-
charomyces cerevisiae and Candida albicans are dimers of
W30 000 M
r
subunits, which do not show sequence similarity
with phosphoglucomutases. A human cDNA encoding a
phosphomannomutase homologous to the fungal enzyme
has recently been cloned [12] from a liver library and the
corresponding gene (PMM1) shown to be present on chromo-
some 22. The chromosomal localization of PMM1 excludes
that mutations in this gene are responsible for CDG syndrome
type I.
The purpose of the present work is to compare the proper-
ties of the PMM1 enzyme with those of phosphomannomu-
tases present in rat liver and in human cells, to investigate the
possibility of the existence of di¡erent isozymes.
2. Materials and methods
2.1. Materials
Chemicals were from Sigma or Merck. [Q-
32
P]ATP was from Amer-
sham. Phosphomannose isomerase was from Sigma; other auxiliary
enzymes and NADP were from Boehringer. Mannose-1,6-bisphos-
phate, prepared as in [6], was puri¢ed by chromatography on Dowex
AG 1-X8 (200^400 mesh; formate form) equilibrated with 50 mM
ammonium formate, pH 5.0; elution was performed with a stepwise
gradient of NaCl. The puri¢ed product was titrated by measuring the
mannose-6-phosphate liberated after a 60 min incubation at 95³C in
0.1 M HCl. Recombinant human phosphomannomutase was prepared
and puri¢ed to homogeneity as previously described [12]. Mannose-6-
[
32
P]phosphate was prepared from mannose and [Q-
32
P]ATP, and pu-
ri¢ed as previously described for glucose-6-[
32
P]phosphate [13]. Ex-
tracts of human liver, lymphocytes and ¢broblasts were prepared as
in [6].
2.2. Partial puri¢cation of rat liver phosphomannomutase
The livers of eight rats were homogenized in 4 vols. of a bu¡er
containing 25 mM HEPES, pH 7.1, 250 mM sucrose, 100 mM
NaCl and 1 mM dithiothreitol ; the homogenate was centrifuged for
15 min at 15 000Ug and a 6^22% poly(ethylene glycol) fraction was
prepared from the supernatant [14]. This fraction was resuspended in
0.6 vol. (compared to the initial homogenate) of bu¡er A (25 mM
HEPES, pH 7.1, containing 1 mM dithiothreitol), clari¢ed by centri-
fugation and applied onto a DEAE-Sepharose (Pharmacia) column
(2.5U40 cm). The column was washed with 400 ml of bu¡er A and
developed with a NaCl gradient (0^500 mM in 2U250 ml of bu¡-
er A). The most active fractions were pooled, concentrated 10-fold by
ultra¢ltration in an Amicon pressure cell (YM-10) and applied onto a
Sephacryl S-200 (Pharmacia) column equilibrated with bu¡er A con-
taining 100 mM NaCl.
2.3. Preparation of polyclonal antibodies and Western blots
For preparation of antiserum, New Zealand rabbits were injected
subcutaneously with 500 Wg of homogeneous human PMM1 [12] in
Freund's complete adjuvant. The injection was repeated twice at 3-
week intervals and blood was collected 10 days after the last injection.
Western blots were performed and developed as in [15].
2.4. Enzyme and protein assays
Unless otherwise indicated, phosphomannomutase was assayed
spectrophotometrically at 30³C in a mixture containing 50 mM
HEPES, pH 7.1, 5 mM MgCl
2
, 0.25 mM NADP, 10 Wg/ml yeast
glucose-6-phosphate dehydrogenase, 10 Wg/ml phosphoglucose iso-
merase, 3.5 Wg/ml phosphomannose isomerase, 0.1 mM mannose-1-
phosphate and 10 WM mannose-1,6-bisphosphate. Phosphoglucomu-
tase was assayed as in [6]. One unit of enzyme is the amount catalys-
ing the formation of 1 Wmol of product per minute under the assay
conditions described above. Protein was assayed according to Brad-
ford [16] with bovine serum albumin as a standard.
2.5. Labelling of the enzyme with mannose-6-[
32
P]phosphate
Phosphomannomutase (typicallyW10 Wg of PMM1) was incubated
at 0³C with 1 WM mannose-6-phosphate, 100 000 c.p.m. of mannose-
6-[
32
P]phosphate, the indicated concentrations of mannose-1,6-bi-
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sphosphate, 25 mM HEPES, pH 7.1, 5 mM MgCl
2
and 0.1 mg bovine
serum albumin in a ¢nal volume of 100 Wl. The reaction was arrested
by addition of 250 Wl of 5% ice-cold trichloroacetic acid and the
resulting mixture was ¢ltered on polyethersulfone ¢lters (Supor
0
200 from Gelman), which were washed with 5 ml of 5% trichloroacetic
acid, dried and counted for radioactivity in the presence of 5 ml of
HiSafe2 Packard scintillant. In some experiments, the acidi¢ed mix-
ture was centrifuged for 10 min at 10 000Ug ; the pellet was resus-
pended in 50 Wl of a mixture containing 2.5% SDS, 12% sucrose, 12
mM dithiothreitol, 0.02% Brilliant Blue and 50 mM Tris-HCl, pH 6.8.
These samples were loaded onto 10% SDS polyacrylamide gels, which
were run for 5 h at 0³C and 20 V/cm. The gels were dried and radio-
activity was localized with a PhosphorImager apparatus (Molecular
Dynamics).
3. Results and discussion
3.1. Partial puri¢cation of rat liver phosphomannomutase
Phosphomannomutase was partially puri¢ed from rat liver
by a procedure involving poly(ethylene glycol) precipitation
and chromatography on DEAE-Sepharose and on Sephacryl
S-200. As illustrated in Fig. 1A, the peak of phosphomanno-
mutase activity was distinct from that of phosphoglucomutase
activity in the DEAE-Sepharose e¥uent, con¢rming that the
two enzymes are di¡erent proteins [17]. The peaks of the two
mutases were almost coincident in the Sephacryl S-200 col-
umn (Fig. 1B), indicating that phosphomannomutase has a
molecular mass close to that of phosphoglucomutase, a mono-
meric enzyme of about 60 000 M
r
[18]. The speci¢c activity of
the puri¢ed enzyme was W300 mU/mg protein compared to
W3 mU/mg protein in the extract; the yield of the puri¢ca-
tion was about 10%.
3.2. Kinetic properties of human PMM1 and of rat and human
liver phosphomannomutases
Human recombinant PMM1 catalysed the conversion of
both mannose-1-phosphate (K
m
=3.2 WM) and glucose-1-
phosphate (K
m
=6 WM) to the corresponding hexose-6-phos-
phates with a V
max
for both substrates of approximately 46
Wmol/min/mg protein. The enzyme was dependent for its ac-
tivity on the presence of a hexose-bisphosphate, with a K
a
for
mannose-1,6-bisphosphate (Fig. 2) and for glucose-1,6-bis-
phosphate (not shown) of 5 þ 0.2 WM (mean+SEM for
n=3). The lack of speci¢city of PMM1 contrasts with the
narrow speci¢city of mammalian phosphoglucomutases,
which are at least 500-fold more active with glucose-1-phos-
phate than with mannose-1-phosphate [18].
Due to the presence of contaminating phosphoglucomutase,
the activity of rat liver phosphomannomutase could not be
determined with glucose-1-phosphate. This enzyme displayed
a K
m
of 3 WM for mannose-1-phosphate (not shown) and K
a
s
for mannose-1,6-bisphosphate (Fig. 2) and glucose-1,6-bis-
phosphate (not shown) that were signi¢cantly lower
(1.2 þ 0.1 WM) than those of PMM1. A similar value for man-
nose-1-phosphate was observed for the enzyme present in
crude human liver extracts, the K
a
for mannose-1,6-bisphos-
phate (Fig. 2) and glucose-1,6-bisphosphate (not shown) being
equal to 0.9 þ 0.1 WM.
Rat and human liver phosphomannomutases displayed the
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Fig. 1. Elution pro¢le of rat liver phosphomannomutase (b) and
phosphoglucomutase (a) from a DEAE-Sepharose column (A) and
from a Sephacryl S-200 column (B). A poly(ethylene glycol) fraction
obtained from 80 g of liver was applied onto a DEAE-Sepharose
column (2.5U40 cm), which was developed with a NaCl gradient;
5 ml fractions were collected; fractions 31^39 were pooled and con-
centrated before further puri¢cation. In (B) a fraction puri¢ed by
chromatography on DEAE-Sepharose and containing 6.8 U phos-
phomannomutase was applied onto a Sephacryl S-200 column.
Fractions of 1 ml were collected. A
280
was also measured (j).
Fig. 2. Saturation curve of human PMM1 (b), rat liver phospho-
mannomutase (R) and human liver phosphomannomutase (F) with
mannose-1,6-bisphosphate. The enzymic activity was assayed with
100 WM mannose-1-phosphate and the indicated concentrations of
mannose-1,6-bisphosphate. Results are expressed as percentage of
the activities measured with 100 WM mannose-1,6-bisphosphate.
These amounted to 46 (PMM1), 0.3 (rat liver) and 0.009 (human
liver) Wmol/min/mg protein. One representative experiment is shown.
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same pH dependency as PMM1 with an optimum at pH 6.5,
about one unit more acidic than that of rabbit muscle or rat
liver phosphoglucomutase (not shown). The three phospho-
mannomutases showed also the same sensitivity to vanadate
(K
i
=100 WM; not shown), a compound known to inhibit
phosphotranferases that form a phosphoenzyme intermediate
[19]. This value was much higher than the K
i
observed with
the phosphoglucomutases mentioned above (1 WM). Further-
more, the three phosphomannomutases were insensitive to
arsenate, whereas this compound, a known inhibitor of phos-
phoglucomutases [20], inhibited the rat and the human liver
enzymes by about 80% at 5 mM. These results suggested that
rat and human liver phosphomannomutases were most likely
enzymes of the same family as PMM1, but with di¡erent
kinetic properties. Furthermore, the lack of e¡ect of arsenate
on the conversion of mannose-1-phosphate to mannose-6-
phosphate indicated that this assay speci¢cally measures phos-
phomannomutase, without contribution of phosphoglucomu-
tase.
3.3. Phosphoenzyme formation
The sensitivity to vanadate [19] and the dependence on bis-
phosphate esters suggested that the reaction mechanism of
phosphomannomutase involved the formation of a phos-
phoenzyme intermediate. As shown in Fig. 3, incubation of
PMM1 with mannose-6-[
32
P]phosphate in the presence of
mannose-1,6-bisphosphate resulted in the incorporation of
phosphate into the enzyme. The labelling was dependent on
the presence of mannose-1,6-bisphosphate (K
a
of W0.5 WM)
and an inhibition at high concentrations of the hexose-bis-
phosphate was observed. At 5 WM mannose-1,6-bisphosphate,
half-saturation of the labelling was obtained with 18 WM man-
nose-6-phosphate and up to 0.3 mol of phosphate was incor-
porated per mole of enzyme subunit (not shown). The phos-
phoenzyme intermediate that was formed was labile, as
indicated by the fact that it was completely destroyed after
a 10 min incubation at 20³C in 1 M NaOH or in a 0.2 M
hydroxylamine/0.1 M sodium acetate (pH 5.5) mixture. It was
also half-maximally degraded after 10 min of incubation at
50³C in 5% trichloroacetic acid (not shown). These properties,
particularly the sensitivity to hydroxylamine, suggest an acyl-
phosphate bond, as in phosphoaspartate or in phosphogluta-
mate [21,22]. They allow to exclude a phosphohistidine, which
is acid-labile but alkali-stable, and a phosphoserine, which is
alkali-labile (though much less than in the present case) but
stable to acid [23].
The lability of the phosphoenzyme prevented us from iso-
lating a tryptic [
32
P]phosphopeptide for identi¢cation of the
phosphorylated residue. PMM1 appears therefore to belong
to a third class of mutases, distinct from both phosphogluco-
mutases and from phosphoglycerate mutases. The reaction
mechanism of these enzymes is indeed known to involve the
formation of a phosphoserine and a phosphohistidine, respec-
tively [24,25].
Incorporation of phosphate into protein was also observed
upon incubation of the partially puri¢ed rat liver phospho-
mannomutase. In this case a half-maximal stimulation was
observed with 0.1 WM mannose-1,6-bisphosphate (Fig. 3). In
the experiment shown in Fig. 4, we incubated di¡erent frac-
tions of the Sephacryl S-200 column (see Fig. 1B) with 1 WM
mannose-6-[
32
P]phosphate and 0.05 WM mannose-1,6-bisphos-
phate and submitted the samples to SDS-PAGE. Two di¡er-
ent bands of about 30 000 and 60 000 M
r
were labelled; the
elution pro¢le of these polypeptides corresponded to those of
phosphomannomutase and phosphoglucomutase, respectively.
Remarkably, the 30 000 M
r
band migrated a little faster than
PMM1. Phosphoglucomutase was labelled presumably be-
cause of partial conversion of mannose-6-phosphate to glu-
cose-6-phosphate by contaminating phosphoglucose isomerase
and phosphomannose isomerase. The 30 000 M
r
band was no
longer apparent if the denatured samples were incubated for
10 min with 1 M NaOH or 0.2 M NH
2
OH at pH 5.5, whereas
the labelling of the 60 000 M
r
band remained unchanged after
these treatments (not shown). These data con¢rm that rat
liver phosphomannomutase forms a phosphoenzyme with
properties similar to those of PMM1.
Incubation of human liver, lymphocyte or ¢broblast ex-
tracts with mannose-6-[
32
P]phosphate together with man-
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Fig. 3. E¡ect of the concentration of mannose-1,6-bisphosphate on
the formation of a phosphoenzyme. Human recombinant PMM1
(0.45 U; b) or partially puri¢ed rat liver phosphomannomutase (1.5
mU, R) was incubated at 0³C for 30 s in the presence of 1 WM
mannose-6-phosphate and the indicated concentrations of mannose-
1,6-bisphosphate. The results obtained with rat liver phosphoman-
nomutase were multiplied by 50. Each point is the mean of at least
three measurements þ SEM.
Fig. 4. SDS-PAGE analysis of the proteins labelled with mannose-
6-[
32
P]phosphate. Twenty microlitres of the indicated fractions of
the Sephacryl S-200 column shown in Fig. 1B or 0.45 U of PMM1
were incubated with mannose-6-[
32
P]phosphate and 0.05 WM (Se-
phacryl S-200 fractions) or 1 WM (PMM1) mannose-1,6-bisphos-
phate for 30 s at 0³C.
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nose-1,6-bisphosphate resulted in a faint but detectable incor-
poration of phosphate in the 30 000 and the 60 000 M
r
bands
(not shown). Remarkably, the labelling of the 30 000 M
r
band
was not detectable in extracts of cells from patients with phos-
phomannomutase de¢ciency indicating that the 30 000 M
r
polypeptide is either missing or inactive in CDG syndrome
type I.
3.4. Reactivity of phosphomannomutases with antibodies
directed against PMM1
Western blots were performed to check if the W30 000 M
r
polypeptide present in human cell extracts was the same as
PMM1. No polypeptide reacted with antibodies directed
against PMM1 when samples from liver, lymphocytes and
¢broblasts (containing between 0.25 and 0.7 mU phospho-
mannomutase) were tested (not shown). Controls run in par-
allel with PMM1 indicated that the technique allowed the
detection of 0.01 mU of this enzyme. These data show that
the principal phosphomannomutase present in human liver,
lymphoblasts and ¢broblasts is not PMM1. We may, how-
ever, not exclude that a small proportion (910%) of the ac-
tivity is contributed by PMM1. This enzyme could be respon-
sible for the residual phosphomannomutase activity found in
patients with CDG syndrome type I.
4. Conclusion
The phosphomannomutases present in human and rat livers
have several properties in common with PMM1 including
their sensitivity to pH and to vanadate, their ability to form
a labile phosphoenzyme intermediate and their subunit molec-
ular mass of about 30 kDa. However, they di¡er from this
enzyme in their higher sensitivity to hexose-bisphosphates and
in their lack of reactivity with antibodies directed against
PMM1. Taken together these data indicate that they represent
a di¡erent isozyme of the same protein family. This second
phosphomannomutase isozyme is most likely mutated in car-
bohydrate-de¢cient glycoprotein syndrome type I. We have
preliminary data in favour of this hypothesis (Matthijs, Cassi-
man and Van Schaftingen, unpublished results).
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